CDP Equity, the investment arm of Italian state lender Cassa Depositi e Prestiti, has purchased a 23.5% stake in Angelini Pharma for €1bn, the companies announced today. The deal values the privately held pharmaceutical group at roughly €4.3bn, reflecting a premium for its portfolio of central nervous system treatments and consumer health brands.
Angelini Pharma, headquartered in Rome, is one of Italy’s largest family-owned drugmakers. The company has been investing heavily in neuroscience and pain management therapies, areas that have attracted significant investor attention amid rising global demand for mental health treatments. The fresh capital from CDP Equity is expected to accelerate Angelini’s research programmes and support its push into new markets, including the UK and other European countries.
For CDP Equity, the acquisition aligns with its strategy of backing strategic domestic industries with long-term growth potential. The move mirrors a broader trend of state-backed investment vehicles increasing their exposure to European healthcare, a sector seen as resilient to economic cycles. Analysts noted that the deal could prompt rival bids or partnerships, particularly as larger pharmaceutical groups seek bolt-on acquisitions to bolster pipeline assets.
The transaction is subject to regulatory approvals but is expected to close later this year. Angelini Pharma’s founding family will retain majority control, with CDP Equity taking a minority seat on the board. The company’s existing management team will remain in place, according to a joint statement.
While the FTSE 100 showed little direct reaction, healthcare-focused funds and UK-listed pharmaceutical stocks such as Hikma Pharmaceuticals and Dechra Pharmaceuticals saw modest gains in afternoon trading, as investors interpreted the deal as a positive signal for sector valuations. The broader market context remains cautious, with the FTSE 100 up 0.3% on the day, driven by defensive sectors.